Spinogenix, a clinical-stage biopharmaceutical company, announced that enrollment is open in Australia for its phase 2 clinical trial (NCT06427668) evaluating its investigational agent SPG302 as a treatment for patients with AD. SPG302, a once-a-day pill, has a unique ability to restore synapses, which are the key connections between neurons that allow patients to think, plan, remember, and control motor functions. It may serve as a first-in-class approach to treating AD, for which there are no approved therapies that operate on synaptic function.
- Mechanism: Synaptic loss is a key feature of dementia, and preclinical studies are exploring drugs that can restore or protect synaptic connections in the brain. One such compound, PTI-125 (simufilam), works by stabilizing a protein called filamin A, which is involved in maintaining the structure of synapses.
- Results: Animal studies have shown that PTI-125 can improve memory and cognitive function without causing significant side effects.
- Current Stage: Moving toward Phase 3 trials after promising preclinical and early clinical results
https://www.neurologylive.com/view/early-clinical-development-once-daily-spg302-alzheimer-disease